H. Mitsuya

发表

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.

H. Mitsuya, T. Shirasaka, R. Yarchoan, 1995, Antiviral research.

Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.

S. Steinberg, B. Anderson, H. Mitsuya, 1995, The Journal of infectious diseases.

Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.

B. Anderson, T. Shirasaka, R. Yarchoan, 1994, Antiviral research.

Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells

H. Mitsuya, A. Yamada, J. Imbach, 1995, Antimicrobial agents and chemotherapy.

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

S. Broder, T. Shirasaka, H. Mitsuya, 1993, The Journal of clinical investigation.

Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.

Y. Yen, B. Zhou, H. Mitsuya, 1998, Biochemical pharmacology.

In Vitro Evaluation of Experimental Agents for Anti‐HIV Activity

D. Richman, V. Johnson, H. Mitsuya, 1993, Current protocols in immunology.

Highly Accurate, Specific And Sensitive Quantitation By Droplet Digital PCR Reveals The Stability of Intrahepatic Hepatitis B Virus cccDNA

Y. Morine, N. Chuaypen, P. Tangkijvanich, 2021 .

Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors.

B. Robbins, A. Fridland, H. Mitsuya, 1991, Advances in experimental medicine and biology.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine.

M. Currens, D. Cooney, A. Fridland, 1990, Biochemical and biophysical research communications.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

H. Mitsuya, S. Broder, J. Mcmahon, 1986, Biochemical pharmacology.

Potentiation of The Anti-HIV Activity of Zalcitabine and Lamivudine by a CTP Synthase Inhibitor, 3-Deazauridine

H. Mitsuya, H. Mitsuya, W. Gao, 2000, Nucleosides, nucleotides & nucleic acids.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.

S. Broder, D. Cooney, A. Fridland, 1991, Molecular pharmacology.

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

S. Broder, D. Cooney, A. Fridland, 1987, Biochemical pharmacology.

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

H. Mitsuya, W. Gao, D. Johns, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.

J. Driscoll, H. Mitsuya, W. Gao, 1995, Biochemical pharmacology.

Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

S. Broder, R. Yarchoan, D. Cooney, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

S. Broder, J. Balzarini, D. Cooney, 1986, Biochemical pharmacology.

Chemistry and anti-HIV activity of 2'-β-fluoro-2',3'-dideoxyguanosine

T. Shirasaka, V. Marquez, M. Siddiqui, 1994 .

Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

H. Mitsuya, W. Gao, D. Johns, 1994, Molecular pharmacology.

In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells.

S. Broder, D. Gilbert, D. Cooney, 1991, The Journal of infectious diseases.

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.

D. Norbeck, D. Kempf, J. Erickson, 1994, AIDS research and human retroviruses.

Synthesis and Anti‐HIV Activity of a Novel Series of Isomeric Dideoxynucleosides

D. Richman, H. Mitsuya, D. Huryn, 1990 .

Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides.

H. Mitsuya, W. Gao, D. Johns, 1994, Analytical Biochemistry.

2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.

H. Mitsuya, W. Gao, D. Johns, 1996, Molecular Pharmacology.

Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.

H. Mitsuya, M. Tanaka, W. Gao, 1999, Molecular pharmacology.

The Cellular Metabolism of AzdU

R. Schinazi, J. Sommadossi, H. Mitsuya, 1990 .

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations

J. Weinstein, D. Norbeck, D. Kempf, 1992, Antimicrobial Agents and Chemotherapy.

Mouse and human GTPBP2, newly identified members of the GP-1 family of GTPase.

S. Senju, Y. Nishimura, H. Kudo, 2000, Biochemical and biophysical research communications.

In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.

J. Weinstein, T. Shirasaka, H. Mitsuya, 1995, Antiviral Research.

Activation of interleukin-2 receptor gene by forskolin and cyclic AMP analogues.

S. Narumiya, T. Nikaido, J. Yodoi, 1987, Biochemical and biophysical research communications.

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2

N. Ohmagari, J. Takeuchi, Y. Kito, 2021, medRxiv.

COVID-19 breakthrough infections and pre-infection neutralizing antibody

W. Sugiura, N. Ohmagari, J. Takeuchi, 2021, medRxiv.

HIV-1 expression induced by anti-cancer agents in latently HIV-1-infected ACH2 cells.

M. Zajac-Kaye, T. Ueno, H. Mitsuya, 1995, Biochemical and biophysical research communications.

Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance

H. Mitsuya, P. D. Yin, D. Das, 2006, Cellular and Molecular Life Sciences.

Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.

T. Shirasaka, J. Driscoll, D. Cooney, 1994, Molecular Pharmacology.

Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides.

J. Driscoll, D. Cooney, H. Mitsuya, 1993, Molecular Pharmacology.